Obesity has been described as a 'public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasising the link between being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 – explains those trends in commercial terms. In two of the largest national markets for anti-obesity treatments - the US and UK - over 20% of the population are seriously overweight. Obesity is a major risk factor in a number of other serious disorders, particularly diabetes and heart disease. Importantly, the financial burden of obesity and its associated conditions - both direct and indirect costs - are vast. Obesity is a serious, chronic condition with an emerging market for therapeutic products, as we show in this study. High socioeconomic costs and increasing prevalence are inspiring government initiatives to deal with the problem, with obesity becoming one of the most prominent global health concerns worldwide. Visiongain recognizes the contribution of drugs in this important emerging market, as diet and exercise are frequently not successful alone. We predict that new classes of drugs will invigorate the market - driving total sales in the next decade. In this report you will find out about those treatments, especially their sales potential.
Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the market:
• A global forecast for the anti-obesity drugs market with comprehensive discussions
• Sales forecasts for the current-leading drugs
• Assessment of new drug releases, both therapeutically and commercially
• Sales forecasts for the leading national anti-obesity markets, as well as for emerging national markets
• Discussion of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-obesity drug sector
• Extensive analysis of pipeline developments, including avenues for future research
• Discussion of current un-met and under-met needs in the anti-obesity market, revealing both therapeutic needs and commercial opportunities.
Why you should buy this report:
• To receive a comprehensive analysis of the prospects for anti-obesity therapies from 2009-2024, including predicted revenues, growth rates and other key metrics
• To identify key pipeline developments, the most promising therapy classes and potential methods of treatment
• To discover the important drivers and restraints for the global anti-obesity market, including factors affecting leading national markets
• To find out where the global anti-obesity market is heading - both technologically and commercially - from the present onwards.
This report is essential reading for anyone in the pharmaceutical and healthcare sector with an interest in obesity and related conditions. Purchasing this report will help you to recognise those important market opportunities and understand the possibilities there.
Companies Listed
7TM Pharma
Abbott
Ache Laboratories
Actavis
Alizyme
American Home Products
Amylin
Arena
AstraZeneca
Athersys
Barcelona University
Bayer
Biovitrum
Bristol-Myers Squibb
Clinuvel
Compellis
Council for Scientific and Industrial Research
Duke University
Eli Lilly
EMEA
Emisphere
EMS
Epix
FDA
Forbes Medi-Tech
Gate Pharmaceuticals
Genaera
GlaxoSmithKline
Graceway Pharma
GW Pharmaceuticals
Han Wha
Hanmi
Inova Pharma
Johnson & Johnson
Kalypsys
Kissei
Kyorin
Louisiana State University
Medley
Merck & Co.
NeuroSearch
Novartis
Novo Nordisk
Nycomed Pharma
OBEcure
Orexigen
OSI Pharmaceuticals
Pfizer
Phytopharm
Roche
Sanofi-Aventis
Shionogi
Sirtris Pharmaceuticals
Solvay
Surface Logix
Takeda
Teva
The Burnham Institute
Transition
TransTech
URL Pharma
Vernalis
Vivus
Wyeth Pharmaceuticals
Visiongain Ltd.
4th Floor,
BSG House,
226-236 City Road,
London
EC1V 2QY
United Kingdom
Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/
Or http://www.visiongain.com
